Head & Neck Cancers | Specialty

Giants of Cancer Care Inductee Announced as Next ASCO President

December 19th 2019

Everett E. Vokes, MD, FASCO, who is a Giants of Cancer Care® recipient for Head and Neck Cancer, has been named the next president of ASCO for the 2021 to 2022 term.

Dr. Ferris on Combining STING Agonists With Checkpoint Inhibitors in Head and Neck Cancer

November 27th 2019

Robert L. Ferris, MD, PhD, discusses combining STING agonists with checkpoint inhibitors in head and neck cancer.

Dr. Gross on the Prognosis of Cutaneous Squamous Cell Carcinoma of the Head and Neck

November 22nd 2019

Neil D. Gross, MD, FACS, discusses the prognosis of patients who are diagnosed with cutaneous squamous cell carcinoma of the head and neck.

Pembrolizumab Regimens Approved in EU for Frontline PD-L1+ HNSCC

November 20th 2019

The European Commission has approved pembrolizumab as a monotherapy or in combination with platinum and 5-FU chemotherapy for the frontline treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma and PD-L1 expression (composite positive score ≥1) on their tumors.

Dr. Saba on Immunotherapy/Radiation Combo in Head and Neck Cancer

October 31st 2019

Nabil F. Saba, MD, FACP, discusses the potential benefit of immunotherapy in combination with radiation in head and neck cancer.

Dr. Saba on Anticipated Research in Head and Neck Cancer

October 31st 2019

Nabil F. Saba, MD, FACP, director, Head and Neck Medical Oncology Program, Winship Cancer Institute of Emory University, and professor, Department of Hematology and Medical Oncology, Department of Otolaryngology, Emory University School of Medicine, discusses anticipated research in head and neck cancer.

SITC Introduces Guidelines for Anti–PD-1 Therapy in HNSCC

October 31st 2019

Based on strong findings for efficacy and safety, as well as FDA approvals, the Society for Immunotherapy of Cancer has issued the first guidelines for the use of immunotherapy agents in patients with recurrent or metastatic head and neck squamous cell carcinoma.

EU Panel Backs Pembrolizumab Regimens for Frontline HNSCC

October 18th 2019

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of pembrolizumab as a monotherapy or in combination with platinum and 5-FU as frontline treatment for patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma and PD-L1 expression on their tumors.

Notable RET Inhibitor Trials Underway

October 18th 2019

The Next Steps in RET Inhibitor Research

October 18th 2019

Using RET Inhibitors in Clinical Practice

October 18th 2019

RET Inhibitor Trial Updates at ASCO and ESMO

October 18th 2019

How BLU-667 Has Changed the Treatment Landscape

October 18th 2019

ESMO 2019 LIBRETTO-001 Trial Updates

October 18th 2019

LOXO-292 in Patients With RET-Fusion Lung Cancer

October 18th 2019

LIBRETTO-001 Regimen Overview

October 18th 2019

RET Testing in Papillary and Medullary Thyroid Cancer

October 18th 2019

The Importance of NGS Testing

October 18th 2019

RET Treatment: Novel Compounds to Replace Current TKIs

October 18th 2019

Multikinase TKIs for NSCLC and Medullary Thyroid Cancer

October 18th 2019